In my opinion, if we want to attract investment in research, inflating the prices is not the way to go.
In order to justify including provisions in the free trade agreement on reforming the drug intellectual property regime, people said that this would make Canada more competitive and allow it to obtain the lion's share of investment in R&D. I would like to point to the fact that we included these provisions and imposed no conditions. Having omitted to do so, we will not be obtaining the spinoff benefits we would like to see.